News & Updates
Showing Pharmacy articles
Showing
Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.
Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.
Long-term statin users at risk of colon cancer
Use of statins does not appear to be chemopreventive against colorectal cancer (CRC), and no significant association exists between total cholesterol level and CRC risk, a study has found. In addition, long-term statin use may increase the risk of colon cancer.
Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.
Do antihypertensive drugs raise odds of COVID-19 diagnosis, death?
Antihypertensive therapy (AHT) may be used safely during the COVID-19 pandemic, as no evidence suggest that it can increase the risk of SARS-CoV-2 infection or death, according to a UK study. In addition, most classes of antihypertensives are negatively associated with COVID-19 diagnosis.
